Contents
Academic literature on the topic 'Smart Start Program (N.C.)'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Smart Start Program (N.C.).'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Smart Start Program (N.C.)"
1
Molteni, Erika, Marta Bianca Maria Ranzini, Elena Beretta, Marc Modat, and Sandra Strazzer. "Individualized Prognostic Prediction of the Long-Term Functional Trajectory in Pediatric Acquired Brain Injury." Journal of Personalized Medicine 11, no. 7 (July 18, 2021): 675. http://dx.doi.org/10.3390/jpm11070675.
Full textAbstract:
In pediatric acquired brain injury, heterogeneity of functional response to specific rehabilitation treatments is a key confound to medical decisions and outcome prediction. We aimed to identify patient subgroups sharing comparable trajectories, and to implement a method for the early prediction of the long-term recovery course from clinical condition at first discharge. 600 consecutive patients with acquired brain injury (7.4 years ± 5.2; 367 males; median GCS = 6) entered a standardized rehabilitation program. Functional Independent Measure scores were measured yearly, until year 7. We classified the functional trajectories in clusters, through a latent class model. We performed single-subject prediction of trajectory membership in cases unseen during model fitting. Four trajectory types were identified (post.prob. > 0.95): high-start fast (N = 92), low-start fast (N = 168), slow (N = 130) and non-responders (N = 210). Fast responders were older (chigh = 1.8; clow = 1.1) than non-responders and suffered shorter coma (chigh = −14.7; clow = −4.3). High-start fast-responders had shorter length of stay (c = −1.6), and slow responders had lower incidence of epilepsy (c = −1.4), than non-responders (p < 0.001). Single-subject trajectory could be predicted with high accuracy at first discharge (accuracy = 0.80). In conclusion, we stratified patients based on the evolution of their response to a specific treatment program. Data at first discharge predicted the response over 7 years. This method enables early detection of the slow responders, who show poor post-acute functional gains, but achieve recovery comparable to fast responders by year 7. Further external validation in other rehabilitation programs is warranted.
2
Pizer, J., A. LaRoche, R. Sawyer, B. Arredondo, B. Mizuki, and C. Knoop. "C-38 Telehealth Dementia Management in a Memory Care Unit: Survey Response Rates and Quality of Life." Archives of Clinical Neuropsychology 34, no. 6 (July 25, 2019): 1067. http://dx.doi.org/10.1093/arclin/acz034.200.
Full textAbstract:
Abstract This feasibility study assessed changes in patient, staff, and family member ratings over time in a program using technology in patient care on an inpatient dementia unit in a nursing home. Method Dementia patients [N = 17; 50% Female; Age M (SD) = 84.56 (7.12); CDR M (SD) = 2.24 (5.17); MoCA M (SD) = 6.67 (.75)], caregivers (N = 17), and staff (N = 27) at a locked memory unit of a long-term care facility in the southern U.S. consented and enrolled in an individualized care program that implemented telehealth visits between a neuropsychologist and residents with staff. The start and end dates of the group varied due to new admissions and deaths. A feasibility study using a repeated measures design was conducted with monthly data collected from questionnaires (Quality of Life (QoL), Professional Care Team Burden (PCTB) Scale, and Zarit Caregiver Burden Inventory). Results QoL in residents as rated by staff was stable over a five-month interval [Baseline M (SD) = 37.94 (7.28); Month-5 M (SD) = 37.13(5.96), p = 0.98]. PCTB and Zarit responses were adequate at baseline (96.3% and 94.4%); however, due to poor response rates at Month 5 (14.3% and 27.2%), comparisons weren’t possible. Conclusion Changes in patient quality of life were not found over a five-month period. However, due to the severity and progression of dementia, a neutral finding may be positive. Anecdotally, perceptions of the program were positive. However, due to low survey response rates, we cannot accurately translate the benefits to the staff and family. Future studies should assess improving response rate or alternate forms of data collection. Generalizability is limited by size and setting.
3
Lob, Sibylle, Krystyna Kazmierczak, Janet Raddatz, Daryl DePestel, Katherine Young, Mary Motyl, and Daniel F. Sahm. "718. Activity of Ceftolozane–Tazobactam and Ceftazidime–Avibactam Against Clinical P. aeruginosa Isolates Collected in United States and Canada—SMART 2018." Open Forum Infectious Diseases 6, Supplement_2 (October 2019): S323. http://dx.doi.org/10.1093/ofid/ofz360.786.
Full textAbstract:
Abstract Background Ceftolozane–tazobactam (C/T) is an antipseudomonal cephalosporin combined with a β-lactamase inhibitor. The combination was cleared by FDA and EMA and is approved in the United States and over 60 countries worldwide. Using clinical isolates collected in the United States and Canada as part of the global SMART surveillance program, we compared the activity of C/T and ceftazidime–avibactam (CAZ/AVI) against P. aeruginosa isolates and subsets nonsusceptible (NS) to selected antimicrobial agents. Methods In 2018, 31 clinical laboratories from United States and Canada collected up to 250 consecutive, aerobic or facultatively anaerobic, Gram-negative pathogens (GNP) from blood, intra-abdominal, urinary, and lower respiratory tract infections. A total of 6,178 GNP were collected, of which 1,138 (18.4%) were P. aeruginosa. MICs were determined using CLSI broth microdilution and interpreted with CLSI 2019 breakpoints. Results The MIC distributions of C/T and CAZ/AVI against 1,138 P. aeruginosa are shown below. The modal MIC value for C/T was ≥2 doubling dilutions lower than that for CAZ/AVI, and it was ≥3 dilutions lower than the C/T CLSI susceptible breakpoint, whereas the modal MIC value for CAZ/AVI was 2 dilutions lower than its susceptible breakpoint. Among all P. aeruginosa isolates, percentages of susceptibility were 96.0% (C/T), 93.8% (CAZ/AVI), 76.6% (CAZ and cefepime), 67.0% (imipenem [IMI]), 74.0% (meropenem [MEM]), 71.5% (piperacillin–tazobactam [TZP]), and 64.9% (aztreonam). Among subsets of nonsusceptible isolates, susceptibilities to C/T and CAZ/AVI were 83.5% and 74.4%, respectively (CAZ-NS subset, n = 266), 91.0% and 85.1% (IMI-NS, n = 376), 87.5% and 80.1% (MEM-NS, n = 296), 87.0% and 79.6% (TZP-NS, n = 324), and 72.4% and 57.8% among isolates nonsusceptible to all tested β-lactams (n = 116). Conclusion The activity of C/T exceeded that of CAZ/AVI and other tested comparators against a recent collection of clinical isolates of P. aeruginosa, including subsets of isolates nonsusceptible to other β-lactams. Susceptibilities to C/T were 6–14 percentage points higher than observed for CAZ/AVI among β-lactam-NS subsets. C/T promises to be an important treatment option for patients with antimicrobial-resistant P. aeruginosa infections. Disclosures All authors: No reported disclosures.
4
Massengill, Macy M., Thiago V. Silva, and Daniel H. Poole. "Setting the Cycle for Reproductive Success with a Pre-synchronization Program in Postpartum Beef Cows." Journal of Animal Science 99, Supplement_2 (May 1, 2021): 23. http://dx.doi.org/10.1093/jas/skab096.040.
Full textAbstract:
Abstract Previous experiments from our laboratory determined that postpartum beef cows with a functional corpus luteum (CL) at the start of an estrous synchronization protocol have greater pregnancy success to FTAI than those that did not have a CL. Therefore, it was hypothesized that incorporation a presynchronization program prior to FTAI in postpartum cows will improve pregnancy rates. The goal of this project was to compare the effectiveness of a presynchronization program prior to the 7-d CO-Synch+CIDR fixed timed artificial insemination (FTAI) protocol in postpartum cows. Postpartum cows (n = 310) at two locations were randomly assigned to receive either the presynchronization program, consisting of 2 PGF2α injections 14 d apart and 11 d prior to the start of the 7-d CO-Synch+CIDR protocol, or the 7-d CO-Synch + CIDR protocol. Following estrus synchronization, all cows were inseminated by trained technicians using semen from bulls of known fertility. Pregnancy status to FTAI was assessed using ultrasonographic diagnosis at 30 d post insemination. Data were analyzed using a MIXED procedure of SAS and examined for effects of inseminator, body condition score (BCS), and location and age. Statistical significance was determined at P < 0.05 and a tendency at 0.05< P < 0.10. Age, BCS, and location did not affect (P > 0.05) pregnancy rates. Cows exposed to the pre-synchronization program tended to have greater AI pregnancy rates compared to cows that did not receive the pre-synchronization program (57.7±5.3 vs. 46.9±5.3%, respectively; P = 0.0687). AI pregnancy rates were greater in cows with >1 ng/mL P4 compared to cows with < 1 ng/mL P4 at the start of FTAI (77.7±7 vs. 55.7±6.2%, respectively; P = 0.0204). Furthermore, AI pregnancy rates were decreased by inseminator C (26.1±7.4) compared to the other inseminators this breeding season (A-54.4±7.9; B- 62.3±5.3; D-57.8±7.2; and E -51.1±5.2; P = 0.0026). Based on these data, incorporating a pre-synchronization program to ensure the presence of a CL at the start of a FTAI protocol may improve pregnancy success in postpartum beef cows.
5
Lob, Sibylle, Krystyna Kazmierczak, Daryl DePestel, Janet Raddatz, Katherine Young, Mary Motyl, and Daniel F. Sahm. "597. Cross-resistance of Ceftolozane-Tazobactam and Imipenem-Relebactam Against Clinical P. aeruginosa Isolates: SMART United States 2016–2018." Open Forum Infectious Diseases 6, Supplement_2 (October 2019): S281. http://dx.doi.org/10.1093/ofid/ofz360.666.
Full textAbstract:
Abstract Background Ceftolozane-tazobactam (C/T) is an antipseudomonal cephalosporin combined with a β-lactamase inhibitor. The combination was cleared by FDA and EMA and is approved in the United States and over 60 countries worldwide. Relebactam (REL) is an inhibitor of class A and C β-lactamases that is in clinical development in combination with imipenem (IMI). Using clinical isolates collected in the United States as part of the global SMART surveillance program, we compared the activity of C/T and IMI/REL against P. aeruginosa (PA) isolates. Methods In 2016–2018, 29 clinical laboratories from the United States collected up to 250 consecutive, aerobic or facultatively anaerobic, gram-negative pathogens (GNP) from blood, intra-abdominal, urinary, and lower respiratory tract infections. A total of 14,606 GNP were collected, of which 2,774 were PA. MICs were determined using CLSI broth microdilution and interpreted with CLSI 2019 breakpoints; IMI breakpoints were used for IMI/REL. Results The activity of C/T and IMI/REL against 2,774 PA is shown (table). Among all PA, 1.8% of isolates were nonsusceptible (NS) to both agents; 4.4% were susceptible (S) to C/T but not to IMI/REL, and 2.9% were susceptible to IMI/REL but not to C/T. Among the subset of isolates collected from patients in ICUs (n = 827), 87.3% were susceptible to both C/T and IMI/REL, 2.7% were nonsusceptible to both agents, 5.8% of isolates were susceptible only to C/T, and 4.2% of isolates were susceptible only to IMI/REL. Among all C/T-NS isolates (all patient locations, n = 132), 61.4% were IMI/REL-S and <30% were susceptible to all other studied β-lactams and fluoroquinolones. Among all IMI/REL-NS isolates (n = 173), 70.5% were C/T-S and <36% were susceptible to all other studied β-lactams and fluoroquinolones. Of the tested agents, only amikacin and colistin exceeded the activity of C/T or IMI/REL against these NS subsets. Conclusion Resistance to C/T or IMI/REL was not common among recent clinical isolates of PA collected in the United States, and both agents promise to be important treatment options. A significant proportion of isolates nonsusceptible to one agent was susceptible to the other, especially among isolates from patients in ICUs. The data suggest that susceptibility to both agents should be tested at hospitals. Disclosures All authors: No reported disclosures.
6
Srivastava, Sheenal, Yumi Patton, David W. Fisher, and Graham R. Wood. "Cotranslational Protein Folding and Terminus Hydrophobicity." Advances in Bioinformatics 2011 (June 6, 2011): 1–8. http://dx.doi.org/10.1155/2011/176813.
Full textAbstract:
Peptides fold on a time scale that is much smaller than the time required for synthesis, whence all proteins potentially fold cotranslationally to some degree (followed by additional folding events after release from the ribosome). In this paper, in three different ways, we find that cotranslational folding success is associated with higher hydrophobicity at the N-terminus than at the C-terminus. First, we fold simple HP models on a square lattice and observe that HP sequences that fold better cotranslationally than from a fully extended state exhibit a positive difference (N−C) in terminus hydrophobicity. Second, we examine real proteins using a previously established measure of potential cotranslationality known as ALR (Average Logarithmic Ratio of the extent of previous contacts) and again find a correlation with the difference in terminus hydrophobicity. Finally, we use the cotranslational protein structure prediction program SAINT and again find that such an approach to folding is more successful for proteins with higher N-terminus than C-terminus hydrophobicity. All results indicate that cotranslational folding is promoted in part by a hydrophobic start and a less hydrophobic finish to the sequence.
7
Ng, Johan Y. Y., Cecilie Thøgersen-Ntoumani, and Nikos Ntoumanis. "Motivation Contagion When Instructing Obese Individuals: A Test in Exercise Settings." Journal of Sport and Exercise Psychology 34, no. 4 (August 2012): 525–38. http://dx.doi.org/10.1123/jsep.34.4.525.
Full textAbstract:
We examined motivation contagion in a hypothetical exercise setting. Exercise science students (n = 164) were provided with quotes of hypothetical male and female obese exercisers displaying different quality of motivation to start an exercise program. We used a 3 (exerciser motivation) × 2 (exerciser gender) × 2 (student gender) between-subjects experimental design to examine students’ (a) motivation to instruct, (b) interpersonal style, (c) perception of barrier efficacy of the exerciser, and (d) effort to identify factors that could maximize the effectiveness of an exercise program for the exerciser. Results showed that students displayed less controlled motivation and rated the exerciser as more capable of overcoming barriers to exercise when they perceived the exerciser to be autonomously motivated. However, students, particularly females, reported more autonomy support and invested more effort toward female exercisers with controlled motivation. Our findings indicate that motivation contagion effects are plausible in exercise settings and may affect interactions between fitness instructors and obese clients.
8
Lob, Sibylle, Krystyna Kazmierczak, Wei-Ting Chen, Yivonne Khoo, Kanchan Balwani, Katherine Young, Mary Motyl, and Daniel F. Sahm. "1581. In Vitro Activity of Ceftolozane/Tazobactam against Pseudomonas aeruginosa from ICU and Non-ICU Patients with Respiratory Tract Infections in the Asia/Pacific region – SMART 2016-2018." Open Forum Infectious Diseases 7, Supplement_1 (October 1, 2020): S788. http://dx.doi.org/10.1093/ofid/ofaa439.1761.
Full textAbstract:
Abstract Background Ceftolozane/tazobactam (C/T) is an antipseudomonal cephalosporin combined with a β-lactamase inhibitor approved by FDA and EMA for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). Elevated antimicrobial resistance rates have been reported among pathogens collected in ICUs. Using isolates collected in Asia/Pacific as part of the global SMART surveillance program, we evaluated the activity of C/T and comparators against P. aeruginosa from patients with respiratory tract infections (RTI) in ICU and non-ICU wards. Methods In 2016-2018, 55 clinical laboratories in 11 Asia/Pacific countries collected 2530 P. aeruginosa isolates from RTI. MICs were determined using CLSI broth microdilution and interpreted with CLSI breakpoints. C/T-nonsusceptible isolates (except those from India) were screened by PCR and sequencing for genes encoding β-lactamases. Results Susceptibility to C/T in Asia/Pacific was 85.3% in ICUs and 92.2% in non-ICUs, 15-23 percentage points and 13-19 percentage points, respectively, higher than to meropenem, cefepime, and piperacillin-tazobactam. C/T maintained activity against 58.8% and 69.4% of meropenem-nonsusceptible isolates from ICU (n=294) and non-ICU patients (n=346), respectively. Acquired β-lactamases were detected in 64% of C/T-nonsusceptible isolates from ICUs (n=90; 54% MBL-positive, 1% GES carbapenemase-positive, 9% ESBL-positive) and in 47% of C/T-NS isolates from non-ICUs (n=86; 33% MBL-positive, 6% GES-carbapenemase-positive, 8% ESBL-positive). The table presents country-level rates of C/T-susceptible and carbapenemase-positive P. aeruginosa for countries with n >20 in both ICU and non-ICU subsets. Table Conclusion In Asia/Pacific overall, C/T maintained susceptibility rates >85% in both ICU and non-ICU wards against P. aeruginosa isolates from RTI, with rates >91% in most countries. Susceptibility was lower in countries with higher rates of carbapenemase-positive P. aeruginosa. C/T could provide an important treatment option for RTI infections caused by P. aeruginosa in the Asia/Pacific region. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Krystyna Kazmierczak, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Wei-Ting Chen, MD, Merck, Sharp & Dohme, Taiwan (Employee) Yivonne Khoo, PhD, Merck, Sharp & Dohme, Malaysia (Employee) Kanchan Balwani, MBBS, MS, Merck, Sharp & Dohme, Hong Kong (Employee) Katherine Young, MS, Merck & Co., Inc. (Employee, Shareholder)Merck & Co., Inc. (Employee, Shareholder) Mary Motyl, PhD, Merck & Co, Inc (Employee, Shareholder) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)
9
Gan, JK, AU Yap, JW Cheong, N. Arista, and CBK Tan. "Bulk-Fill Composites: Effectiveness of Cure With Poly- and Monowave Curing Lights and Modes." Operative Dentistry 43, no. 2 (March 1, 2018): 136–43. http://dx.doi.org/10.2341/16-304-l.
Full textAbstract:
SUMMARY This study compared the effectiveness of cure of bulk-fill composites using polywave light-emitting diode (LED; with various curing modes), monowave LED, and conventional halogen curing lights. The bulk-fill composites evaluated were Tetric N-Ceram bulk-fill (TNC), which contained a novel germanium photoinitiator (Ivocerin), and Smart Dentin Replacement (SDR). The composites were placed into black polyvinyl molds with cylindrical recesses of 4-mm height and 3-mm diameter and photopolymerized as follows: Bluephase N Polywave High (NH), 1200 mW/cm2 (10 seconds); Bluephase N Polywave Low (NL), 650 mW/cm2 (18.5 seconds); Bluephase N Polywave soft-start (NS), 0-650 mW/cm2 (5 seconds) → 1200 mW/cm2 (10 seconds); Bluephase N Monowave (NM), 800 mW/cm2 (15 seconds); QHL75 (QH), 550 mW/cm2 (21.8 seconds). Total energy output was fixed at 12,000 mJ/cm2 for all lights/modes, with the exception of NS. The cured specimens were stored in a light-proof container at 37°C for 24 hours, and hardness (Knoop Hardness Number) of the top and bottom surfaces of the specimens was determined using a Knoop microhardness tester (n=6). Hardness data and bottom-to-top hardness ratios were subjected to statistical analysis using one-way analysis of variance/Scheffe's post hoc test at a significance level of 0.05. Hardness ratios ranged from 38.43% ± 5.19% to 49.25% ± 6.38% for TNC and 50.67% ± 1.54% to 67.62% ± 6.96% for SDR. For both bulk-fill composites, the highest hardness ratios were obtained with NM and lowest hardness ratios with NL. While no significant difference in hardness ratios was observed between curing lights/modes for TNC, the hardness ratio obtained with NM was significantly higher than the hardness ratio obtained for NL for SDR.
10
Walther, Ashley, Devin O'Piela, Cara Pannell, Amy Sharn, Heather Schier, and Carolyn Gunther. "Simple Suppers – Gone Online (SS-Go): Feasibility of a Family Meals Program Transitioned From In-Person to Online in the COVID-19 Pandemic." Current Developments in Nutrition 5, Supplement_2 (June 2021): 255. http://dx.doi.org/10.1093/cdn/nzab029_056.
Full textAbstract:
Abstract Objectives Adapt and pilot Simple Suppers (SS)—a site-based 8-week family meals program for Head Start (HS) families offered in fall, winter, and spring—to an online platform using a community-based participatory approach, in response to COVID-19. Methods Researchers collaborated with community partners and HS families to adapt the core components (caregiver education; child education; family meal) of SS to an online format. Feasibility outcomes (demand: response rate, attendance, retention; acceptability: satisfaction; implementation: fidelity, cost; limited effectiveness: diet, weight status) were measured: pre, post, or throughout programming via count, survey, focus group, or direct measure. Baseline demographic data were also collected. Results The research-community team came to consensus on: a) utilizing e-methods families were accustomed to in local HS programs and elementary schools (Google Classroom; Zoom; YouTube videos) for the educational components; b) enhancing the educational components with a supplemental program-specific weekly magazine (“SS Digest”); c) creating a weekly meal kit delivery for the family meal component (“SS Chef's Crate”); and d) adding an additional week to programming (8 to 9) to orient families to the new online format. 13 of 40 families enrolled in HS participated in the fall session of SS-GO programming (32.5% response rate) and mean (SD) weekly attendance was 4.0 (0.86). 11 of the 13 families engaged in the research, and 10 of 11 completed pre- and post-test data collection (91% retention). Survey and focus group data revealed high levels of satisfaction for SS-GO. Weekly lessons were delivered as intended 92.8% of the time, and Chef's Crates were received by families 100% of the time. Mean (SD) food cost of programming was $212.33 (66.06) or $16.33 per family. Limited effectiveness data are forthcoming. Baseline mean (SD) caregiver age was 32.5 (9.32) years (n = 11), 100% (n = 11) female, 72.7% (n = 11) Black, mean (SD) BMI 36.3 (9.31), 36.4% (n = 4) low income, and 36.4% (n = 11) had low or very low food insecurity. Mean (SD) child age was 3.45 (0.69) (n = 11), 45.5% (n = 5) were female, and had a mean (SD) BMI z-score 0.63 (0.76) (n = 11). Conclusions SS-GO demonstrates feasibility utilizing a community-based participatory approach. Data will guide future iterations of the program—in COVID-19 and after. Funding Sources USDA NIFA CYFAR